Free Trial
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

Galera Therapeutics logo
$0.03 0.00 (-1.52%)
As of 03/28/2025 12:56 PM Eastern

About Galera Therapeutics Stock (NASDAQ:GRTX)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.03
$0.05
52-Week Range
$0.02
$0.24
Volume
1,708 shs
Average Volume
129,560 shs
Market Capitalization
$1.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Remove Ads
Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GRTX Stock News Headlines

DOGE could send 6 AI stocks through the roof
Stay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement from Elon any day now … Thousands of government jobs could be replaced … By a new form of AI. Recently perfected by Musk and his team at xAI.
Newron Pharmaceuticals S.p.A. (NP5.DE)
GRTX Galera Therapeutics, Inc.
See More Headlines

GRTX Stock Analysis - Frequently Asked Questions

Galera Therapeutics' stock was trading at $0.0458 at the beginning of 2025. Since then, GRTX stock has decreased by 29.0% and is now trading at $0.0325.
View the best growth stocks for 2025 here
.

Galera Therapeutics, Inc. (NASDAQ:GRTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.15.

Galera Therapeutics (GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Nextera Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP).

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2025
Next Earnings (Estimated)
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($2.41) per share
Price / Book
-0.01

Miscellaneous

Free Float
47,375,000
Market Cap
$1.77 million
Optionable
Optionable
Beta
2.06
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:GRTX) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners